DODC

DODC is a psychedelic drug from the substituted amphetamine family which acts as an agonist of the 5-HT2A receptor. It is the 3,4-dichloro derivative of the well known psychedelic drug 2,5-Dimethoxy-4-chloroamphetamine (DOC). DODC was first officially published in a patent filed by Gilgamesh Pharmaceuticals in 2020,[1] though anecdotal reports suggest it had been synthesised by clandestine chemists and its activity established several years prior to this.

DODC
Identifiers
  • 1-(2,5-dimethoxy-3,4-dichlorophenyl)propan-2-amine
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC11H15Cl2NO2
Molar mass264.15 g·mol−1
3D model (JSmol)
  • Clc1c(OC)cc(CC(C)N)c(OC)c1Cl

See also

References

  1. WO 2022/006186, Kruegel AC, "Phenalkylamines and Methods of Treating Mood Disorders.", published January 2022, assigned to Gilgamesh Pharmaceuticals.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.